---
title: "Trevi Therapeutics, Inc. (TRVI.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/TRVI.US.md"
symbol: "TRVI.US"
name: "Trevi Therapeutics, Inc."
industry: "Pharmaceuticals"
datetime: "2026-05-20T07:11:50.644Z"
locales:
  - [en](https://longbridge.com/en/quote/TRVI.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TRVI.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TRVI.US.md)
---

# Trevi Therapeutics, Inc. (TRVI.US)

## Company Overview

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.trevitherapeutics.com](https://www.trevitherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -41.21 | 219 | - | - | - |
| PB | 10.92 | 181 | 8.87 | 7.43 | 6.21 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-12T04:00:00.000Z

Total Analysts: **11**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 82% |
| Overweight | 2 | 18% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 13.24 |
| Highest Target | 27.00 |
| Lowest Target | 16.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/TRVI.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/TRVI.US/norm.md)
- [Related News](https://longbridge.com/en/quote/TRVI.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/TRVI.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**